Slideshow

Treating Primary and Secondary Raynaud’s

In this slideshow, we summarize the difference between primary and secondary Raynaud’s phenomenon and recommended treatments.

Raynaud’s phenomenon affects up to five percent of the general population, but for 37 percent of people with the disorder, it leads to connective tissue disease. In this slideshow, we sum up identifying factors for primary Raynaud’s and secondary Raynaud’s as described by Fredrick M. Wigley, M.D., and Nicholas A. Flavahan, Ph.D., two Johns Hopkins University School of Medicine physicians who, on August 11, published a related review article in the New England Journal of Medicine. 

References:

Fredrick M. Wigley, M.D., and Nicholas A. Flavahan, Ph.D. "Raynaud’s Phenomenon," N Engl J Med 2016; 375:556-565August 11, 2016DOI: 10.1056/NEJMra1507638

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Related Content
Early Control of Rheumatoid Arthritis Improves Hemostatic Imbalance
January 10th 2025

Early Control of Rheumatoid Arthritis Improves Hemostatic Imbalance

Victoria Johnson
Emerging Agents in the Treatment of Rheumatic Diseases
October 2nd 2023

Emerging Agents in the Treatment of Rheumatic Diseases

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR Philip J. Mease, MD
Cannabinoid-Based Formula Demonstrates Proof-of-Concept for Treating RA
January 8th 2025

Cannabinoid-Based Formula Demonstrates Proof-of-Concept for Treating RA

Victoria Johnson
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
August 31st 2023

Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis

Nehad Soloman, MD, FACR Andrew Sharobeem, DO, FACR John B. Boone, MD, FACR Madelaine Feldman MD, FACR
Alexander Chaitoff, MD, MPH, Department of Internal Medicine, University of Michigan School of Medicine, and Center for Healthcare Delivery Sciences, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School
January 7th 2025

Gabapentin Does Not Increase Risk of Falls in Older Adults with Fibromyalgia

Victoria Johnson
Naomi Schlesinger, MD, Division of Rheumatology, Spencer Fox Eccles School of Medicine, University of Utah
January 4th 2025

Adherence Low for ULT Dosing ACR Gout Guidelines

Victoria Johnson
© 2025 MJH Life Sciences

All rights reserved.